Research paperIn vitro methods for generating CD8+ T-cell clones for immunotherapy from the naïve repertoire
Introduction
Enhancing or supplementing the body's own immune responses against cancer is a goal of the field of immunotherapy. Although non-specific approaches such as the administration of cytokines can generally augment immune responses, the major current focus for manipulating the cellular immune response to tumors is to target specific antigens associated with malignant cells with vaccines or the transfer of antigen-specific T cells. The tools used for identifying candidate tumor-specific or tumor-associated antigens have been rapidly evolving. One of the first described approaches to identify antigens that can induce T-cell responses has used tumor-reactive T cells isolated from cancer patients as the reagent for screening target cells transfected with a tumor-derived expression library (Boon et al., 1994, Rosenberg, 1999). Currently, analyses of differential gene expression, for example using cDNA microarrays or serial analysis techniques, are the most widely used methods of identifying candidate tumor antigens (Lal et al., 1999, Polyak and Riggins, 2001). With these methods, selection is based on unique or overexpression of the antigen in malignant versus normal cells; however, there is no direct evidence of immunogenicity.
Developing effective methods for evaluating the identified candidate antigens to determine those with the most clinical promise is becoming more important. One strategy is to immunize cancer patients with the antigen and assess immunologic and clinical responses. A potential advantage of this vaccine approach is that the patient's own immune system does the screening for immunogenicity and the work of generating the appropriate immune effector cells; however, there are many candidate antigens to enter into clinical trials with limited basis for prioritization, reproducibly effective vaccine vectors that can induce strong responses have not yet been developed, and, if clear anti-tumor responses are not achieved following vaccination to the selected antigen, defining the qualitative or quantitative reasons for failure and how to proceed can be difficult. Thus, using an in vitro system to screen candidate antigens for immunogenicity before proceeding to in vivo studies has significant advantages.
An alternative approach to vaccination, the adoptive transfer of in vitro generated and expanded T-cell clones, overcomes the obstacle to generating a strong response that can hinder vaccination, as the number and type of cells transferred can be adjusted so that very high in vivo frequencies can be achieved. Thus, adoptive transfer of T cells can potentially be used to determine if an antigenic target should be further pursued and to set goals for vaccine strategies. However, general application of this approach requires the development of efficient in vitro methods for generating and expanding T-cell lines and clones specific for the target antigens of interest.
In vitro methods employing various forms of antigen and stimulator cells as antigen-presenting cells (APC) have been shown to be effective at expanding ex vivo memory T cells (e.g. viral-specific) that have been primed in the host by previous in vivo exposure to the antigen. However, generating and expanding primary immune responses from naïve precursors in vitro has generally been much more difficult, as naïve T cells have more stringent activation and costimulatory requirements. Additionally, since most of the target antigens in tumors are derived from normal self-proteins, the majority of potentially reactive cells will have been deleted during development or maturation in the periphery; thus, with the remaining reactive naïve precursor T cells being rare and predominantly of lower avidity, it is more difficult to isolate T-cell clones of the desired specificity and avidity.
Dendritic cells (DC) are the critical APC for inducing primary T-cell responses, but they represent a diverse and heterogeneous population of cells. Because of their ease of generation, most clinical studies have used DC generated by culture of monocytes in GM-CSF and IL-4; however, multiple protocols exist using varying types of media, serum and maturation signals/cytokines to generate such DC (Jonuleit et al., 1997, Reddy et al., 1997, Bennett et al., 1998, Ridge et al., 1998, Schoenberger et al., 1998, Cella et al., 1999, Lee et al., 2002, Dauer et al., 2003a). Although most “traditional” protocols for generating monocyte-derived DC include a week of culture, recent studies have described the use of mature DC generated from monocytes in only 48 h (“FastDC”) (Dauer et al., 2003a, Obermaier et al., 2003, Xu et al., 2003). Such DC express typical maturation markers, but morphologically appear distinct from the more classical DC, and may have distinct APC functions. The advantage of using DC generated with such a protocol would be significant savings in time and expense (related to cytokine cost) for DC production, as well as potentially distinct stimulatory capacities.
The nature and timing of cytokine exposure will likely impact the outcome of T-cell priming. IL-7 (a cytokine important for naïve T-cell survival, T-cell homeostasis and memory cell expansion) and IL-2 (the canonical T-cell growth factor) are commonly used as supplements for the in vitro generation of T-cell lines (Lynch and Miller, 1994, Walter et al., 1995, Schluns et al., 2000). However, the optimal timing for addition of these cytokines has not been defined. In theory, delaying the addition of such cytokines to later in the stimulation cycle might decrease the “non-specific” expansion of bystander CD8+ cells reactive with irrelevant antigens that have been transiently activated, and this could have an impact on expansion of the desired population.
Finally, while the efficiency of antigen presentation and level of costimulation provided by mature DC are likely critical for efficient priming of naïve T cells, it is less clear if repeated stimulations with DC are either required or beneficial for the efficient expansion of previously primed CD8+ cells. In fact, repeated stimulations with mature DC have been shown to potentially lead to not only deletion of high affinity T cells, but also the broader disappearance of virtually all antigen-specific CD8+ cells, possibly by activation-induced cell death (AICD) (Alexander-Miller et al., 1996, Mehrotra et al., 2003). Whether alternative types of stimulator cells might better expand previously primed antigen-specific CD8+ cells requires further investigation.
To address these issues, we examined a variety of culture conditions and cellular compositions to identify a reliable strategy for in vitro priming and subsequent expansion of antigen-specific CD8+ T cells, including the type of APC used for priming and restimulation, and the timing of addition and nature of supplemental cytokines. Normal healthy donors were used as the source of responder cells for this analysis of primary in vitro responses to minimize the potential that naïve precursors had been exposed to the tumor antigen in vivo. WT1 was chosen as the model tumor-associated antigen to examine, since this recently identified antigen currently is being evaluated in several vaccine trials as a therapeutic target. WT1 is a transcription factor that is normally expressed in several embryonic tissues and detected at low levels in adult cells including renal mesangial cells and hematopoietic stem cells (Little et al., 1999), but is overexpressed by many solid tumors and most leukemias (including AML, ALL and CML) with higher levels of expression correlating with worse prognosis (Bergmann et al., 1997). For comparison, responses to the heteroclitic peptide analogue of an HLA-A⁎0201-restricted epitope (aa26–35) of the Melan-A melanoma antigen, to which primary in vitro responses have been well described, were also studied. This was done, in part, because there is an unusually high frequency of naïve CD8+ T-cell precursors due to positive selection in the thymus (Pittet et al., 1999, Oelke et al., 2000), which greatly simplifies the generation of detectable primary responses.
Section snippets
PBMC donors and cell lines
After informed consent was obtained, PBMC from healthy human donors (both HLA-A⁎0201+ and HLA-A⁎0201−) were harvested by leukapheresis, washed and cryopreserved in aliquots. Leukemia cells, PBMC blasts obtained from a 59-year-old male patient with M5 subtype acute myeloid leukemia, were previously determined to be WT1+ by RT-PCR (kindly provided by Matthias Theobald, University of Mainz, Germany). TM-LCL cells are an EBV-transformed lymphoblastoid cell line used in the Rapid Expansion Protocol
Phenotype of DC2d cells
Various protocols for generating mature monocyte-derived dendritic cells over a 48-h period (instead of the more widely used week-long protocols) have been recently described (Dauer et al., 2003a, Dauer et al., 2003b, Obermaier et al., 2003, Xu et al., 2003). Such shorter culture periods offer practical advantages, but disparities in the methods of monocyte enrichment, provision of maturation signals and the composition of the culture medium have led to variability in the DCs produced with the
Discussion
The ability to generate and expand ex vivo high-avidity CD8+ T cells specific for candidate tumor-associated antigens is essential not only for pursuing adoptive T-cell immunotherapy but also for validating candidate antigens as immunogenic and for obtaining insights into the potential efficacy and safety of the antigen as a therapeutic target. Monocyte-derived DC are readily generated in vitro and have been demonstrated in multiple studies to be very useful as APC for stimulating CD8+ T-cell
Acknowledgements
This work was supported by grants CA33084, CA18029 (Project 7) and CA96669 from the NIH, and by the Leukemia and Lymphoma Society (7040-03). M. Wolfl and J. Kuball are fellows of the Deutsche Krebshilfe (Germany).
References (38)
- et al.
High levels of Wilms' tumor gene (wt1) mRNA in acute myeloid leukemias are associated with a worse long-term outcome
Blood
(1997) - et al.
FastDC derived from human monocytes within 48 h effectively prime tumor antigen-specific cytotoxic T cells
J. Immunol. Methods
(2005) - et al.
A clinical grade cocktail of cytokines and PGE2 results in uniform maturation of human monocyte-derived dendritic cells: implications for immunotherapy
Vaccine
(2002) - et al.
A monocyte conditioned medium is more effective than defined cytokines in mediating the terminal maturation of human dendritic cells
Blood
(1997) - et al.
The use of anti-CD3 and anti-CD28 monoclonal antibodies to clone and expand human antigen-specific T cells
J. Immunol. Methods
(1990) A new era for cancer immunotherapy based on the genes that encode cancer antigens
Immunity
(1999)- et al.
Selective expansion of high- or low-avidity cytotoxic T lymphocytes and efficacy for adoptive immunotherapy
Proc. Natl. Acad. Sci. U. S. A.
(1996) - et al.
Phenotypic analysis of antigen-specific T lymphocytes
Science
(1996) - et al.
Help for cytotoxic-T-cell responses is mediated by CD40 signalling
Nature
(1998) - et al.
IL-15 promotes the survival of naive and memory phenotype CD8+ T cells
J. Immunol.
(2003)
Tumor antigens recognized by T lymphocytes
Annu. Rev. Immunol.
Maturation, activation, and protection of dendritic cells induced by double-stranded RNA
J. Exp. Med.
Dendritic cell differentiation
J. Immunol.
Mature dendritic cells derived from human monocytes within 48 hours: a novel strategy for dendritic cell differentiation from blood precursors
J. Immunol.
Interferon-alpha disables dendritic cell precursors: dendritic cells derived from interferon-alpha-treated monocytes are defective in maturation and T-cell stimulation
Immunology
Pro-inflammatory cytokines and prostaglandins induce maturation of potent immunostimulatory dendritic cells under fetal calf serum-free conditions
Eur. J. Immunol.
Il-12 enhances CD8 T cell homeostatic expansion
J. Immunol.
A public database for gene expression in human cancers
Cancer Res.
Kinetics of dendritic cell activation: impact on priming of TH1, TH2 and nonpolarized T cells
Nat. Immunol.
Cited by (108)
Optimal control design for drug delivery of immunotherapy in chemoimmunotherapy treatment
2023, Computer Methods and Programs in BiomedicineReady for Repair? Gene Editing Enters the Clinic for the Treatment of Human Disease
2020, Molecular Therapy Methods and Clinical DevelopmentCitation Excerpt :However, such an approach involves a heterogeneous T cell population rather than tumor-specific T cells. One solution to this problem would be to increase tumor specificity of circulating T cells in vitro by exposure to tumor-associated antigens.54 Due to the impressive clinical results from checkpoint inhibitors and TILs to treat melanoma, this type of cancer was chosen in the initial preclinical studies on applying immune checkpoint knockout (KO) in ACT using ex vivo gene editing.
A flow cytometry-based method to screen for modulators of tumor-specific T cell cytotoxicity
2020, Methods in EnzymologyThe Bumpy Road to CAR Activation
2019, Molecular TherapyPotential advantages of CD1-restricted T cell immunotherapy in cancer
2018, Molecular Immunology